Carbonyl reduction of bupropion in human liver

Xenobiotica

Volumn 42, Issue 6, 2012, Pages 550-561

  Molnari, Jillissa C ^a,b   Myers, Alan L ^a,c  

^a DRAKE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Carbonyl reductase; hepatic metabolism; inhibition studies

Indexed keywords

AMFEBUTAMONE; CARBONYL DERIVATIVE; CARBONYL REDUCTASE; DRUG METABOLITE; ERYTHROHYDROBUPROPION; GLYCYRRHETINIC ACID; MENADIONE; RADAFAXINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THREOHYDROBUPROPION; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IC 50; LIVER; LIVER CYTOSOL; LIVER METABOLISM; LIVER MICROSOME; REDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ALCOHOL OXIDOREDUCTASES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYTOSOL; ENZYME INHIBITORS; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; NADP; VITAMIN K 3;

EID: 84860559111     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.643416     Document Type: Article

References (56)

1. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. (1994). Cloning and tissue distribution of the human 11 betahydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17.
2. Atalla A, Breyer-Pfaff U, Maser E. (2000). Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3- pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755-769.
3. Benson AM, Hunkeler MJ, Talalay P. (1980). Increase of NAD(P) H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77:5216-5220.
4. DeVane CL, Laizure SC, Stewart JT, Kolts BE, Ryerson EG, Miller RL, Lai AA. (1990). Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 10:328-332.
5. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207.
6. Ebert B, Kisiela M, Malátková P, El-Hawari Y, Maser E. (2010). Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry 49:8499-8511.
7. Endo S, Matsunaga T, Kitade Y, Ohno S, Tajima K, El-Kabbani O, Hara A. (2008). Human carbonyl reductase 4 is a mitochondrial NADPHdependent quinone reductase. Biochem Biophys Res Commun 377:1326-1330.
8. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
9. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123-1129.
10. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
11. Forrest GL, Gonzalez B. (2000). Carbonyl reductase. Chem Biol Interact 129:21-40.
12. Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG. (2007). A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 35:973-980.
13. Goodnick PJ. (1991). Pharmacokinetics of second generation antidepressants: bupropion. Psychopharmacol Bull 27:513-519.
14. Gronau S, Koenig Greger D, Jerg M, Riechelmann H. (2002). 11Betahydroxysteroid dehydrogenase 1 expression in squamous cell carcinomas of the head and neck. Clin Otolaryngol Allied Sci 27:453-457.
15. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238.
16. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
17. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. (1997). Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
18. Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
19. Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695.
20. Jin Y, Penning TM. (2007). Aldo-keto reductases and bioactivation/ detoxication. Annu Rev Pharmacol Toxicol 47:263-292.
21. Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P. (1991). A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 52:450-456.
22. Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. (2002). Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63:181-186.
23. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. (2005). Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226-229.
24. Krozowski Z, Li KX, Koyama K, Smith RE, Obeyesekere VR, Stein- Oakley A, Sasano H, Coulter C, Cole T, Sheppard KE. (1999). The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol 69:391-401.
25. Lai AA, Schroeder DH. (1983). Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 44:82-84.
26. Lakhman SS, Ghosh D, Blanco JG. (2005). Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 33:254-257.
27. Malátková P, Maser E, Wsól V. (2010). Human carbonyl reductases. Curr Drug Metab 11:639-658.
28. Maser E, Friebertshäuser J, Völker B. (2003). Purification, characterization and NNK carbonyl reductase activities of 11betahydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobaccoderived carcinogen. Chem Biol Interact 143-144:435-448.
29. McCollum DL, Greene JL, McGuire DK. (2004). Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drugs Ther 18:329-330.
30. Molnari JC, Hassan HE, Moeller BM, Myers AL. (2010). Drug interaction study between bupropion and ticlopidine in male CF-1 mice. Biol Pharm Bull 34:447-451.
31. Molnari JC, Hassan HE, Myers AL. (2011). Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Eur J Drug Metab Pharmacokinet. [Epub ahead of print]. Northrop D. 1998. On the meaning of Km and V/K. J Chem Educat 75:1153-7.
32. Odermatt A, Nashev LG. (2010). The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 119:1-13.
33. Oppermann U. (2007). Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
34. Oppermann UC, Maser E. (2000). Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144:71-81.
35. Penning TM, Talalay P. (1983). Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. Proc Natl Acad Sci USA 80:4504-4508.
36. Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, Favia AD, Duarte RG, Jörnvall H, KaVanagh KL, Kedishvili N, Kisiela M, Maser E, Mindnich R, Orchard S, Penning TM, Thornton JM, Adamski J, Oppermann U. (2009). The SDR (short-chain dehydrogenase/ reductase and related enzymes) nomenclature initiative. Chem Biol Interact 178:94-98.
37. Petsalo A, Turpeinen M, Tolonen A. (2007). Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 21:2547-2554.
38. Porter SJ, Somogyi AA, White JM. (2000). Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 50:465-471.
39. Posner J, Bye A, Dean K, Peck AW, Whiteman PD. (1985). The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol 29:97-103.
40. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ. (2008). An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
41. Rosemond MJ, Walsh JS. (2004). Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335-361.
42. Schroeder DH. (1983). Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79-81.
43. Segel IH. 1993. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Systems. New York: John Wiley and Sons, Inc.
44. Shimoda K, Shibasaki M, Inaba T, Cheung SW, Someya T, Takahashi S. (1998). Carbonyl reduction of timiperone in human liver cytosol. Pharmacol Toxicol 83:164-168.
45. Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E. (2009). Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology 264:52-60.
46. Slemmer JE, Martin BR, Damaj MI. (2000). Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
47. Soldan M, Nagel G, Losekam M, Ernst M, Maser E. (1999). Interindividual variability in the expression and NNK carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase 1 in human lung. Cancer Lett 145:49-56.
48. Someya T, Inaba T, Tyndale RF, Tang SW, Takahashi S. (1991). Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 5:177-182.
49. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned- Coughlin S. (2004). A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 6:159-166.
50. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, Wilson JT, Manno JE. (2001). Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 41:770-778.
51. Tyndale RF, Kalow W, Inaba T. (1991). Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/ debrisoquine monooxygenase). Br J Clin Pharmacol 31:655-660.
52. Walsh JS, Reese MJ, Thurmond LM. (2002). The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 142:135-154.
53. Wang M. (2006). Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 7:319-323.
54. Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GD, Ahmed MS, Nanovskaya TN. (2010). Bupropion metabolism by human placenta. Biochem Pharmacol 79:1684-1690.
55. Weintraub D. (2001). Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety 13:50-52.
56. Welch RM, Lai AA, Schroeder DH. (1987). Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17:287-298.